IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-05-05 (diariofarma.com)
Health launches its 'wait', which cuts 176 days the deadline for financing innovation since 2020 | @
A few days after Efpia publishes the WAIT report, the Ministry of Health has advanced its data on innovative drug financing deadlines, highlighting a drop in waiting times and greater early availability for patients. With this report, Health also wants to advance in transparency and advertising of accessible public information.
Read more
2025-04-24 (pulsmedycyny.pl)
IQVIA has concluded a contract with the European Medicine Agency - Puls Medicine
QVia has concluded a long -term contract with the European Medicine Agency (EMA). This agreement provides access to data on drug consumption, which is to help solve current problems related to their deficiencies - IQVIA said on April 24.
Read more
2025-04-02 (fiercebiotech.com)
Through a CRO's perspective: Innovative, Agile Solutions In Vaccine Efficacy Testing |
Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence's release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories' Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. | Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence's release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories' Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic.
Read more
2025-03-20 (hankyung.com)
Celltrion, Order in Italy, Stekima |
Celltrion is expanding its bidding results in Italy, one of the five major European countries, with autoimmune disease treatment, and Stecima, which was released in January of this year, opened the bidding performance in two months. The Celltrion Italian subsidiary has recently succeeded in winning Stekima orders from the Ustekima bids held in four state governments, Piemonte, Valle D'Aosta, Liguria, and Sardegna. The combined size of the region is about 10%of the Italian Ustecinumab market, which will be supplied by Stekima by 2028.In the bidding of the adalimumab bids in Lazio, Lombardia, and Umbria, of the 21 Italian governments. 'Uflyma' was a successful bid. Starting this month, Lazio and Lombardia will be supplied with Ulflymas for the next three years and Umbria for two years, according to IQVIA, a pharmaceutical market research firm, with a 43%share in Italy as of the third quarter of last year, continuing the first place after the last quarter.
Read more